## 5th ILROG Continuing Education Conference Radiotherapy in Modern Management of Lymphoma

## Beijing, China May 24-27, 2024

| 24 May, 2024 Arrival \& Registration |  |  |
| :---: | :---: | :---: |
| 25 May, 2024 |  |  |
| 8:00-8:10 | Welcome | Dr. Jie He |
| 8:10-8:20 | Welcome, course info \& housekeeping | Dr. Yexiong Li |
| 8:20-8:30 | Introduction and purpose of course | Dr. Joachim Yahalom |
| 8:30-9:00 | Photo session |  |
| Part 1 | Early stage and radiation as consolidation: Hodgkin's and Diffuse large cell and tips on how to manage | Session Chair: <br> Dr. Lena Specht <br> Dr. Andrea Ng |
| 9:00-9:30 | Consolidation radiation in the PET-era: Balancing efficacy and toxicity with modern RT (Classical HL) | Dr. Lena Specht |
| 9:30-10:00 | Consolidation radiation in the PET-era: Balancing efficacy and toxicity with modern RT (DLBCL) | Dr. Andrea Ng |
| 10:00-10:20 | Coffee break |  |
| 10:20-10:50 | DLBCL: Using genomics to guide frontline systemic therapy | Dr. Weili Zhao |
| 10:50-11:20 | DLBCL: Novel treatments for DLBCL | Dr. Andrew Zelenetz |
| 11:20-12:00 | Cases presented/Panel Discussion/Q \& A Lena Specht, Andrea Ng, Andrew Zelenetz, Weili Zhao, Liling Zhang |  |
|  | Translation Assistant | Danna, Jingru Zhu |
| 12:00-1:30 | Lunch \& Satellite symposium |  |
| Part 2 | Car T therapy and bispecific | Session Chair: <br> Dr. Bouthaina Dabaja <br> Dr. George Mikhaeel |
| 1:30-1:50 | Latest developments in cellular therapy | Dr. Weidong Han |
| 1:50-2:10 | Latest developments in bispecific | Dr. Yuqin Song |
| 2:10-2:35 | Available data on using radiation as both bridging and priming therapy | Dr. Brandon Imber |
| 2:35-3:00 | Practical RT application: choice of dose, fractionation, volume, and technique with plenty of case examples | Dr. Bouthaina Dabaja |
| 3:00-3:30 | Cases presented/Panel Discussion/Q \& A <br> Brandon Imber, Bouthaina Dabaja, Yuqin Song, Weidong Han, Xiaorong Hou |  |
|  | Translation Assistant | Yunpeng Wu, Yuan Zong |
| 3:30-3:50 | Coffee break |  |
| Part 3 | Extranodal NK/T cell lymphoma | Session Chair: <br> Dr. Yexiong Li <br> Dr. Shunan Qi |
| 3:50-4:15 | Risk-adapted treatment of ENKTCL | Dr. Yexiong Li |
| 4:15-4:35 | Multi-omic molecular characterization of ENKTCL | Dr. Jinxin Bei |


| 4:35-5:00 | New drugs and immunotherapy in ENKTCL | Dr. Qingqing Cai |
| :---: | :---: | :---: |
| 5:00-5:30 | Cases presented/Panel Discussion/Q \& A Jinxin Bei, Qingqing Cai, Liang Wang, Shengyu Zhou, Yexiong Li |  |
|  | Translation Assistant | Yuqi Wu, Jingru Zhu |
| Banquet 6:30PM |  |  |
| 26 May, 2024 |  |  |
| Part 4 | Hypofractionation and technology | Session Chair: <br> Dr. Lena Specht <br> Dr. Bouthaina Dabaja |
| 8:00-8:25 | Hypofractionation for lymphomas - new option in lymphoma radiation therapy based on experience from the COVID pandemic | Dr. Lena Specht |
| 8:25-8:50 | Imaging for precision in lymphoma radiation therapy | Dr. George Mikhaeel |
| 8:50-9:15 | Proton therapy for lymphomas - where do we stand? | Dr. Bouthaina Dabaja |
| 9:15-9:45 | Cases presented/Panel Discussion/Q \& A Lena Specht, George Mikhaeel, Yong Yang, Xin Liu |  |
|  | Translation Assistant | Yuan Zong, Zhuanbo Yang |
| 9:45-10:10 | Coffee break |  |
| Part 5 | Low grade lymphomas and MALT | Session Chair: <br> Dr. Brandon Imber <br> Dr. Shunan Qi |
| 10:10-10:40 | Modern radiotherapy for the management of Indolent lymphomas - integration of lower doses, systemic therapies and molecular features | Dr. Brandon Imber |
| 10:40-11:10 | 2024 perspectives on systemic therapy for indolent lymphomas - moving beyond CD20 and chemotherapy | Dr. Andrew Zelenetz |
| 11:10-11:35 | Harnessing big data to support the role of radiotherapy for MZL and MALT | Dr. Shunan Qi |
| 11:35-12:00 | Cases presented/Panel Discussion/Q \& A <br> Brandon Imber, Andrew Zelentez, Shengyu Zhou, Liang Wang, Shunan Qi |  |
|  | Translation Assistant | Yongbo Xiang, Yunpeng Wu |
| 12:00-1:30 | Lunch \& Satellite symposium |  |
| Part 6 | Myeloma | Session Chair: <br> Dr. Joachim Yahalom <br> Dr. Umberto Ricardi |
| 1:30-2:00 | Growing Numbers, Growing Options- State-of-the-art Management and Current Challenges | Dr. Saad Usmani (to be confirmed) |
| 2:00-2:30 | Solitary Plasmacytoma: New Data, Current Management and Dose Challenges | Dr. Umberto Ricardi |
| 2:30-3:00 | The Growing Use of RT in Multiple Myeloma: What we Know and What we Don't - for improving efficacy? | Dr. Alexandra Dreyfuss |
| 3:00-3:20 | Data and challenges of managing MM in China | Dr. Lugui Qiu |
| 3:20-3:50 | Cases presented/Panel Discussion/Q \& A <br> Saad Usmani (to be confirmed), Umberto Ricardi, Alexandra Dreyfuss, Lugui Qiu |  |
|  | Translation Assistant | Zhuoran Li, Jing Yang |
| 4:00 | Close |  |
| 27 May, 2024 Departure |  |  |

